H.C. Wainwright raised the firm’s price target on Kala Pharmaceuticals (KALA) to $35 from $12 and keeps a Buy rating on the shares ahead of the CHASE trial readout, which is expected in late September. The firm increased the probability of approval for KPI-012 to 35%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Kala Pharmaceuticals price target raised to $33 from $15 at Oppenheimer
- Kala Pharmaceuticals initiated with an Outperform at Mizuho
- Kala Pharmaceuticals management to meet with Piper Sandler
- Kala Pharmaceuticals initiated with an Outperform at LifeSci Capital
- Kala Pharmaceuticals Appoints Todd Bazemore as CEO